Drug Trial Radar · NCT06818643
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
270
Planned (sponsor's estimate)
Start
Mar 25, 2025
Primary completion
Feb 8, 2028
Study completion Mar 25, 2031
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Feb 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main goal of this study is to learn about the safety of MK-3120 and if people tolerate it.
Conditions
- Advanced Solid Tumors
- Malignant Neoplasm
Interventions
MK-3120Biological
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 19 months
- Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 18 months
Locations
49 sites in 12 countries. Site status is shown where the registry gives one.
The University of Alabama at Birmingham ( Site 1005)
Birmingham, Alabama · Recruiting
University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1003)
Miami, Florida · Recruiting
John Theurer Cancer Center at Hackensack University Medical Center ( Site 1009)
Hackensack, New Jersey · Recruiting
NEXT Oncology ( Site 1010)
Austin, Texas · Recruiting
NEXT Oncology ( Site 1011)
Houston, Texas · Recruiting
NEXT Oncology ( Site 1012)
Irving, Texas · Recruiting
Virginia Commonwealth University ( Site 1008)
Richmond, Virginia · Recruiting
Centro de Estudios Clínicos SAGA ( Site 0033)
Santiago, Region M. de Santiago, Chile · Active not recruiting
Fundación Arturo López Pérez ( Site 0031)
Santiago, Region M. de Santiago, Chile · Recruiting
Pontificia Universidad Catolica de Chile ( Site 0032)
Santiago, Region M. de Santiago, Chile · Recruiting
Bradford Hill Centro de Investigaciones Clinicas ( Site 0030)
Santiago, Region M. de Santiago, Chile · Active not recruiting
Peking University First Hospital ( Site 0180)
Beijing, Beijing Municipality, China · Active not recruiting
Chongqing Cancer Hospital ( Site 0186)
Chongqing, Chongqing Municipality, China · Active not recruiting
Hunan Cancer Hospital ( Site 0181)
Changsha, Hunan, China · Recruiting
The First Hospital of Jilin University ( Site 0185)
Changchun, Jilin, China · Active not recruiting
West China Hospital Sichuan University ( Site 0187)
Chengdu, Sichuan, China · Active not recruiting
Institut Paoli Calmettes ( Site 0053)
Marseille, Bouches-du-Rhone, France · Active not recruiting
Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer-Medical Oncology ( Site 0054)
Rennes, Ille-et-Vilaine, France · Active not recruiting
Centre Oscar Lambret ( Site 0051)
Lille, Nord, France · Active not recruiting
Gustave Roussy ( Site 0050)
Villejuif, Val-de-Marne, France · Active not recruiting
Rambam Health Care Campus ( Site 0082)
Haifa, Israel · Active not recruiting
Rabin Medical Center ( Site 0081)
Petah Tikva, Israel · Active not recruiting
Sheba Medical Center ( Site 0080)
Ramat Gan, Israel · Active not recruiting
Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 0191)
Osaka, Japan · Recruiting
National Cancer Center Hospital East ( Site 0190)
Kashiwa, Chiba, Japan · Recruiting
Cancer Institute Hospital of JFCR ( Site 0192)
Koto, Tokyo, Japan · Active not recruiting
Radboudumc ( Site 0091)
Nijmegen, Gelderland, Netherlands · Recruiting
Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0090)
Amsterdam, North Holland, Netherlands · Active not recruiting
Amsterdam UMC, locatie VUmc ( Site 0093)
Amsterdam, North Holland, Netherlands · Active not recruiting
Erasmus Medisch Centrum ( Site 0092)
Rotterdam, South Holland, Netherlands · Recruiting
Pratia Poznan ( Site 0105)
Poznan, Greater Poland Voivodeship, Poland · Recruiting
Pratia MCM Krakow ( Site 0106)
Krakow, Lesser Poland Voivodeship, Poland · Active not recruiting
Narodowy Instytut Onkologii ( Site 0100)
Warsaw, Masovian Voivodeship, Poland · Recruiting
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie ( Site 0104)
Koszalin, West Pomeranian Voivodeship, Poland · Recruiting
Seoul National University Hospital ( Site 0150)
Seoul, South Korea · Recruiting
Severance Hospital Yonsei University Health System ( Site 0151)
Seoul, South Korea · Recruiting
Asan Medical Center ( Site 0153)
Seoul, South Korea · Recruiting
Samsung Medical Center ( Site 0152)
Seoul, South Korea · Recruiting
Hospital Universitario Virgen de la Victoria ( Site 0114)
Málaga, Spain · Active not recruiting
Institut Català d'Oncologia - L'Hospitalet ( Site 0113)
L'Hospitalet de Llobregat, Barcelona, Spain · Active not recruiting
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.